Trial Profile

A Single Arm Phase II Study to Evaluate Efficacy of T-DM1 With Palbociclib in the Treatment of Patients With Metastatic HER2 Positive Breast Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 16 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Palbociclib (Primary) ; Trastuzumab emtansine (Primary)
Indications Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
Focus Therapeutic Use
Acronyms T-DM1

Most Recent Events

22 Dec 2022 Status changed from active, no longer recruiting to completed.
15 Feb 2022 Planned primary completion date changed from 1 Dec 2023 to 22 Dec 2022.
15 Feb 2022 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com